Integrated signaling in heterodimers and receptor mosaics of different types of GPCRs of the forebrain: Relevance for schizophrenia

Journal of Neural Transmission

Volumn 116, Issue 8, 2009, Pages 923-939

  Fuxe, Kjell ^a   Marcellino, Daniel ^a   Woods, Amina S ^b   Giuseppina, Leo ^c,d   Antonelli, Tiziana ^e   Ferraro, Luca ^e   Tanganelli, Sergio ^e   Agnati, Luigi F ^c,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d IRCCS SAN CAMILLO HOSPITAL   (Italy)

^e UNIVERSITY OF FERRARA   (Italy)

Author keywords

5HT2A; A2A; CB 1; Cerebral cortex; D2; Hallucinogenic drugs; Heterodimers receptor mosaics; MGluR5; NTS1 D3; Prefrontal cortex; Schizophrenia; Ventral striatum

Indexed keywords

ADENOSINE A2A RECEPTOR; CANNABINOID 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLUTAMIC ACID; HETERODIMER; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 5; NEUROTENSIN RECEPTOR; NEUROTENSIN RECEPTOR 1; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

ALLOSTERISM; BRAIN CORTEX; CELL MEMBRANE; CONFORMATIONAL TRANSITION; CORPUS STRIATUM; FOREBRAIN; GLOBUS PALLIDUS; HUMAN; LONG TERM DEPRESSION; LONG TERM POTENTIATION; NERVE CELL NETWORK; NERVE PROJECTION; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; THALAMUS;

ANIMALS; BASAL GANGLIA; CEREBRAL CORTEX; GLOBUS PALLIDUS; HUMANS; NEURONS; PROSENCEPHALON; PROTEIN MULTIMERIZATION; RECEPTORS, G-PROTEIN-COUPLED; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 67651253080     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-008-0174-9     Document Type: Review

References (167)

1. L Adermark DM Lovinger 2007 Retrograde endocannabinoid signaling at striatal synapses requires a regulated postsynaptic release step Proc Natl Acad Sci USA 104 20564 20569
2. GK Aghajanian GJ Marek 2000 Serotonin model of schizophrenia: emerging role of glutamate mechanisms Brain Res Brain Res Rev 31 302 312
3. GK Aghajanian WE Foote MH Sheard 1968 Lysergic acid diethylamide: sensitive neuronal units in the midbrain raphe Science 161 706 708
4. LF Agnati K Fuxe F Benfenati N Battistini 1983 Neurotensin in vitro markedly reduces the affinity in subcortical limbic 3H-N-propylnorapomorphine binding sites Acta Physiol Scand 119 459 461 (Pubitemid 14214775)
5. LF Agnati S Ferre C Lluis R Franco K Fuxe 2003 Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons Pharmacol Rev 55 509 550
6. LF Agnati S Ferre S Genedani 2006 Allosteric modulation of dopamine D2 receptors by homocysteine J Proteome Res 5 3077 3083
7. L Agnati D Guidolin S Genedani P Arhem A Forni N Andreoli K Fuxe 2007 Role of cooperativity in protein folding and protein mosaic assemblage: relevance for protein conformational diseases Curr Protein Pept Sci 8 460 470
8. LF Agnati D Guidolin G Leo K Fuxe 2007 A boolean network modelling of receptor mosaics relevance of topology and cooperativity J Neural Transm 114 77 92
9. LF Agnati G Leo S Genedani N Andreoli D Marcellino A Woods L Piron D Guidolin K Fuxe 2008 Structural plasticity in G-protein coupled receptors as demonstrated by the allosteric actions of homocysteine and computer-assisted analysis of disordered domains Brain Res Rev 58 459 474
10. GE Alexander MD Crutcher MR DeLong 1990 Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions Prog Brain Res 85 119 146
11. NE Anden A Dahlstroem K Fuxe K Larsson L Olson U Ungerstedt 1966 Ascending monoamine neurons to the telencephalon and diencephalon Acta Physiol Scand 67 313 326
12. NE Anden H Corrodi K Fuxe T Hokfelt 1968 Evidence for a central 5-hydroxytryptamine receptor stimulation by lysergic acid diethylamide Br J Pharmacol 34 1 7
13. NE Anden H Corrodi K Fuxe 1971 Hallucinogenic drugs of the indolealkylamine type and central monoamine neurons J Pharmacol Exp Ther 179 236 249
14. NE Anden H Corrodi K Fuxe JL Meek 1974 Hallucinogenic phenylethylamines: interactions with serotonin turnover and receptors Eur J Pharmacol 25 176 184
15. MB Andersen K Fuxe T Werge J Gerlach 2002 The adenosine A2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys Behav Pharmacol 13 639 644
16. M Andersson A Terasmaa K Fuxe I Stromberg 2005 Subchronic haloperidol increases CB(1) receptor binding and G protein coupling in discrete regions of the basal ganglia J Neurosci Res 82 264 272
17. M Andersson A Usiello A Borgkvist 2005 Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons J Neurosci 25 8432 8438
18. T Antonelli K Fuxe MC Tomasini E Mazzoni LF Agnati S Tanganelli L Ferraro 2007 Neurotensin receptor mechanisms and its modulation of glutamate transmission in the brain: relevance for neurodegenerative diseases and their treatment Prog Neurobiol 83 92 109
19. HS Bateup P Svenningsson M Kuroiwa S Gong A Nishi N Heintz P Greengard 2008 Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs Nat Neurosci 11 932 939
20. D Belin BJ Everitt 2008 Cocaine seeking habits depend upon dopamine-dependent serial connectivity linking the ventral with the dorsal striatum Neuron 57 432 441
21. MA Benneyworth Z Xiang RL Smith EE Garcia PJ Conn E Sanders-Bush 2007 A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis Mol Pharmacol 72 477 484
22. B Berger AM Thierry JP Tassin MA Moyne 1976 Dopaminergic innervation of the rat prefrontal cortex: a fluorescence histochemical study Brain Res 106 133 145
23. HG Bernstein S Krause D Krell 2007 Strongly reduced number of parvalbumin-immunoreactive projection neurons in the mammillary bodies in schizophrenia: further evidence for limbic neuropathology Ann N Y Acad Sci 1096 120 127
24. A Borgkvist D Marcellino K Fuxe P Greengard G Fisone 2008 Regulation of DARPP-32 phosphorylation by Delta(9)-tetrahydrocannabinol Neuropharmacology 54 1 31 35
25. NA Breslin RL Suddath G Bissette CB Nemeroff P Lowrimore DR Weinberger 1994 CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates Schizophr Res 12 35 41
26. R Caceda B Kinkead CB Nemeroff 2006 Neurotensin: role in psychiatric and neurological diseases Peptides 27 2385 2404
27. M Canals D Marcellino F Fanelli 2003 Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer J Biol Chem 278 46741 46749
28. A Carlsson 1988 The current status of the dopamine hypothesis of schizophrenia Neuropsychopharmacology 1 179 186
29. A Carlsson ML Carlsson 2008 Adaptive properties and heterogeneity of dopamine D(2) receptors: pharmacological implications Brain Res Rev 58 374 378
30. A Carlsson M Lindqvist 1963 Effect Of chlorpromazine or haloperidol on formation of 3 methoxytyramine and normetanephrine in mouse brain Acta Pharmacol Toxicol (Copenh) 20 140 144
31. P Carriba O Ortiz K Patkar 2007 Striatal adenosine A(2A) and cannabinoid CB(1) receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids Neuropsychopharmacology 32 11 2249 2259
32. P Carriba G Navarro F Ciruela 2008 Detection of heteromerization of more than two proteins by sequential BRET-FRET Nat Methods 5 727 733
33. D Centonze N Battista S Rossi NB Mercuri A Finazzi-Agro G Bernardi P Calabresi M Maccarrone 2004 A critical interaction between dopamine D2 receptors and endocannabinoids mediates the effects of cocaine on striatal gabaergic transmission Neuropsychopharmacology 29 1488 1497
34. F Ciruela J Burgueno V Casado 2004 Combining mass spectrometry and pull-down techniques for the study of receptor heteromerization: dDirect epitope-epitope electrostatic interactions between adenosine A2A and dopamine D2 receptors Anal Chem 76 5354 5363
35. FC Colpaert 2003 Discovering risperidone: the LSD model of psychopathology Nat Rev Drug Discov 2 315 320
36. PJ Conn G Battaglia MJ Marino F Nicoletti 2005 Metabotropic glutamate receptors in the basal ganglia motor circuit Nat Rev Neurosci 6 787 798
37. TJ Cullen MA Walker N Parkinson R Craven TJ Crow MM Esiri PJ Harrison 2003 A postmortem study of the mediodorsal nucleus of the thalamus in schizophrenia Schizophr Res 60 157 166
38. JT Cummins G von Euler K Fuxe SO Ogren LF Agnati 1987 Chronic imipramine treatment reduces (+)2-[125I]iodolysergic acid, diethylamide but not 125I-neuropeptide Y binding in layer IV of rat cerebral cortex Neurosci Lett 75 152 156
39. DC D'Souza WM Abi-Saab S Madonick K Forselius-Bielen A Doersch G Braley R Gueorguieva TB Cooper JH Krystal 2005 Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction Biol Psychiatry 57 594 608
40. A Dahlstroem K Fuxe 1964 Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons Acta Physiol Scand Suppl Suppl 232 231 255
41. P Danos 2004 Pathology of the thalamus and schizophrenia: an overview Fortschr Neurol Psychiatr 72 621 634
42. P Danos B Baumann A Kramer HG Bernstein R Stauch D Krell P Falkai B Bogerts 2003 Volumes of association thalamic nuclei in schizophrenia: a postmortem study Schizophr Res 60 141 155
43. P Danos A Schmidt B Baumann HG Bernstein G Northoff R Stauch D Krell B Bogerts 2005 Volume and neuron number of the mediodorsal thalamic nucleus in schizophrenia: a replication study Psychiatry Res 140 281 289
44. A Del Arco F Mora AH Mohammed K Fuxe 2007 Stimulation of D2 receptors in the prefrontal cortex reduces PCP-induced hyperactivity, acetylcholine release and dopamine metabolism in the nucleus accumbens J Neural Transm 114 185 193
45. J Diaz C Pilon B Le Foll C Gros A Triller JC Schwartz P Sokoloff 2000 Dopamine D3 receptors expressed by all mesencephalic dopamine neurons J Neurosci 20 8677 8684
46. Z Diaz-Cabiale K Fuxe JA Narvaez S Finetti T Antonelli S Tanganelli L Ferraro 2002 Neurotensin-induced modulation of dopamine D2 receptors and their function in rat striatum: counteraction by a NTR1-like receptor antagonist Neuroreport 13 763 766
47. Z Diaz-Cabiale M Vivo A Del Arco 2002 Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats: interactions with adenosine A(2A) and dopamine D(2) receptors Neurosci Lett 324 154 158
48. PR Dobner AY Deutch J Fadel 2003 Neurotensin: dual roles in psychostimulant and antipsychotic drug responses Life Sci 73 801 811
49. KA Dorph-Petersen JN Pierri Z Sun AR Sampson DA Lewis 2004 Stereological analysis of the mediodorsal thalamic nucleus in schizophrenia: volume, neuron number, and cell types J Comp Neurol 472 449 462
50. BJ Everitt K Fuxe FT Hokfelt G Jonsson 1975 Role of monoamines in the control by hormones of sexual receptivity in the female rat J Comp Physiol Psychol 89 556 572
51. D Feifel TL Reza DJ Wustrow MD Davis 1999 Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist J Pharmacol Exp Ther 288 710 713 (Pubitemid 29119685)
52. L Ferraro MC Tomasini K Fuxe LF Agnati R Mazza S Tanganelli T Antonelli 2007 Mesolimbic dopamine and cortico-accumbens glutamate afferents as major targets for the regulation of the ventral striato-pallidal GABA pathways by neurotensin peptides Brain Res Rev 55 144 154
53. L Ferraro MC Tomasini R Mazza K Fuxe J Fournier S Tanganelli T Antonelli 2008 Neurotensin receptors as modulators of glutamatergic transmission Brain Res Rev 58 365 373
54. S Ferre G von Euler B Johansson BB Fredholm K Fuxe 1991 Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes Proc Natl Acad Sci USA 88 7238 7241
55. S Ferre WT O'Connor P Snaprud U Ungerstedt K Fuxe 1994 Antagonistic interaction between adenosine A2A receptors and dopamine D2 receptors in the ventral striopallidal system: implications for the treatment of schizophrenia Neuroscience 63 765 773
56. S Ferre P Popoli R Rimondini R Reggio J Kehr K Fuxe 1999 Adenosine A2A and group I metabotropic glutamate receptors synergistically modulate the binding characteristics of dopamine D2 receptors in the rat striatum Neuropharmacology 38 129 140
57. S Ferre M Karcz-Kubicha BT Hope 2002 Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function Proc Natl Acad Sci USA 99 11940 11945
58. S Ferre F Ciruela M Canals 2004 Adenosine A2A-dopamine D2 receptor-receptor heteromers: targets for neuro-psychiatric disorders Parkinsonism Relat Disord 10 265 271
59. S Ferre LF Agnati F Ciruela C Lluis AS Woods K Fuxe R Franco 2007 Neurotransmitter receptor heteromers and their integrative role in 'local modules': The striatal spine module Brain Res Rev 55 55 67
60. K Fuxe 1965 Evidence for the existence of monoamine neurons in the central nervous system. IV. Distribution of monoamine nerve terminals in the central nervous system Acta Physiol Scand Suppl Suppl 247 237
61. Fuxe K (1970) Biological and pharmacological theories. In: Bobon DP, Janssen PAJ, Bobon J (eds) The neuroleptics. S. Karger, Basel, pp 121-122
62. K Fuxe B Holmstedt G Jonsson 1972 Effects of 5-methoxy-N, N-dimethyltryptamine on central monoamine neurons Eur J Pharmacol 19 25 34
63. Fuxe K, Everitt BJ, Agnati L, Fredholm BB, Jonsson G (1976) On the biochemistry and pharmacology of hallucinogens. In: Kemali D, Bartholini G, Richter D (eds) Schizophrenia today. Pergamon, Oxford, pp 135-157
64. Fuxe K, Andersson K, Schwarcz R (1979) Studies on different types of DA nerve terminals in the forebrain and their possible interactions with hormones and with neurons containing GABA, glutamate and opiod peptides. In: Poirier LJ, Sourkes TL, Bedard PJ et al (eds) Advances in neurology, vol 24. Raven, New York, pp 199-214
65. K Fuxe MF Celani M Martire I Zini M Zoli LF Agnati 1984 l-Glutamate reduces the affinity of [3H]N-propylnorapomorphine binding sites in striatal membranes Eur J Pharmacol 100 127 130
66. K Fuxe WT O'Connor T Antonelli PG Osborne S Tanganelli LF Agnati U Ungerstedt 1992 Evidence for a substrate of neuronal plasticity based on pre- and postsynaptic neurotensin-dopamine receptor interactions in the neostriatum Proc Natl Acad Sci USA 89 5591 5595
67. K Fuxe S Ferre P Snaprud G von Euler B Johansson BB Fredholm 1993 Antagonistic A2A/D2 receptor interactions as a basis for adenosine/dopamine interactionns in the central nervous system Drug Dev Res 28 374 380
68. K Fuxe LF Agnati K Jacobsen 2003 Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease Neurology 61 S19 S23
69. Fuxe K, Ferre S, Woods A, Rivera A, Hoistad M, Franco R, Kehr J, Agnati L (2003b) Novel strategies for the treatment of Parkinson's disease: focus on receptor-receptor interactions in the basal ganglia. In: Kehr J, Fuxe K, Ungerstedt U, Svensson T (eds) Monitoring molecules in neuroscience. Karolinska University Press, Stockholm, pp 199-202
70. K Fuxe S Ferre M Canals 2005 Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function J Mol Neurosci 26 209 220
71. K Fuxe M Canals M Torvinen 2007 Intramembrane receptor-receptor interactions: a novel principle in molecular medicine J Neural Transm 114 49 75
72. K Fuxe A Dahlstrom M Hoistad 2007 From the Golgi-Cajal mapping to the transmitter-based characterization of the neuronal networks leading to two modes of brain communication: wiring and volume transmission Brain Res Rev 55 17 54
73. K Fuxe S Ferre S Genedani R Franco LF Agnati 2007 Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function Physiol Behav 92 210 217
74. K Fuxe D Marcellino S Genedani L Agnati 2007 Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson's disease Mov Disord 22 1990 2017
75. K Fuxe D Marcellino A Rivera 2008 Receptor-receptor interactions within receptor mosaics: impact on neuropsychopharmacology Brain Res Rev 58 415 452
76. J Gandia J Galino OB Amaral A Soriano C Lluis R Franco F Ciruela 2008 Detection of higher-order G protein-coupled receptor oligomers by a combined BRET-BiFC technique FEBS Lett 582 2979 2984
77. A Giuffrida LH Parsons TM Kerr F Rodriguez de Fonseca M Navarro D Piomelli 1999 Dopamine activation of endogenous cannabinoid signaling in dorsal striatum Nat Neurosci 2 358 363
78. M Glass CC Felder 1997 Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor J Neurosci 17 5327 5333
79. J Gonzalez-Maeso T Yuen BJ Ebersole 2003 Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex J Neurosci 23 8836 8843
80. J Gonzalez-Maeso NV Weisstaub M Zhou 2007 Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior Neuron 53 439 452
81. J Gonzalez-Maeso RL Ang T Yuen 2008 Identification of a serotonin/glutamate receptor complex implicated in psychosis Nature 452 93 97
82. Gozes I (2005) Receptor-receptor interactions among heptaspanning membrane receptors: from structure to function. In: Wenner-Gren Foundation symposium on receptor-receptor interactions among heptaspanning membrane receptors: from structure to function, vol, special issue of J Mol Neurosci 26 (Nos. 2, 3). Humana press, Stockholm, pp 109-305
83. AA Grace 2000 Gating of information flow within the limbic system and the pathophysiology of schizophrenia Brain Res Brain Res Rev 31 330 341
84. HJ Groenewegen M Trimble 2007 The ventral striatum as an interface between the limbic and motor systems CNS Spectr 12 887 892
85. HJ Groenewegen HW Berendse SN Haber 1993 Organization of the output of the ventral striatopallidal system in the rat: ventral pallidal efferents Neuroscience 57 113 142
86. HJ Groenewegen CI Wright AV Beijer 1996 The nucleus accumbens: gateway for limbic structures to reach the motor system? Prog Brain Res 107 485 511
87. W Guo E Urizar M Kralikova JC Mobarec L Shi M Filizola JA Javitch 2008 Dopamine D2 receptors form higher order oligomers at physiological expression levels EMBO J 27 2293 2304
88. EV Gurevich JN Joyce 1999 Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons Neuropsychopharmacology 20 60 80
89. SN Haber JL Fudge NR McFarland 2000 Striatonigrostriatal pathways in primates form an ascending spiral from the shell to the dorsolateral striatum J Neurosci 20 2369 2382
90. K Hakansson S Galdi J Hendrick G Snyder P Greengard G Fisone 2006 Regulation of phosphorylation of the GluR1 AMPA receptor by dopamine D2 receptors J Neurochem 96 482 488
91. L Heimer 2000 Basal forebrain in the context of schizophrenia Brain Res Brain Res Rev 31 205 235
92. + currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade J Neurosci 20 8987 8995
93. J Hillion M Canals M Torvinen 2002 Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors J Biol Chem 277 18091 18097
94. A Jansson B Tinner M Bancila D Verge HW Steinbusch LF Agnati K Fuxe 2001 Relationships of 5-hydroxytryptamine immunoreactive terminal-like varicosities to 5-hydroxytryptamine-2A receptor-immunoreactive neuronal processes in the rat forebrain J Chem Neuroanat 22 185 203
95. JN Joyce EV Gurevich 1999 D3 receptors and the actions of neuroleptics in the ventral striatopallidal system of schizophrenics Ann N Y Acad Sci 877 595 613
96. JN Joyce MJ Millan 2005 Dopamine D3 receptor antagonists as therapeutic agents Drug Discov Today 10 917 925
97. PW Kalivas CB Nemeroff AJ Prange Jr 1981 Increase in spontaneous motor activity following infusion of neurotensin into the ventral tegmental area Brain Res 229 525 529
98. PW Kalivas CB Nemeroff AJ Prange Jr 1984 Neurotensin microinjection into the nucleus accumbens antagonizes dopamine-induced increase in locomotion and rearing Neuroscience 11 919 930
99. T Kamiya O Saitoh K Yoshioka H Nakata 2003 Oligomerization of adenosine A2A and dopamine D2 receptors in living cells Biochem Biophys Res Commun 306 544 549
100. CS Kearn K Blake-Palmer E Daniel K Mackie M Glass 2005 Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol Pharmacol 67 1697 1704
101. ZU Khan L Mrzljak A Gutierrez A de la Calle PS Goldman-Rakic 1998 Prominence of the dopamine D2 short isoform in dopaminergic pathways Proc Natl Acad Sci USA 95 7731 7736
102. GG Kinney M Burno UC Campbell LM Hernandez D Rodriguez LJ Bristow PJ Conn 2003 Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents J Pharmacol Exp Ther 306 116 123
103. GG Kinney JA O'Brien W Lemaire 2005 A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models J Pharmacol Exp Ther 313 199 206
104. AC Kreitzer RC Malenka 2007 Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models Nature 445 643 647
105. FM Leweke A Giuffrida D Koethe 2007 Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use Schizophr Res 94 29 36
106. XM Li PB Hedlund K Fuxe 1994 Strong effects of NT/NN peptides on DA D2 receptors in rat neostriatal sections Neuroreport 5 1621 1624
107. JA Lieberman RB Mailman G Duncan L Sikich M Chakos DE Nichols JE Kraus 1998 Serotonergic basis of antipsychotic drug effects in schizophrenia Biol Psychiatry 44 1099 1117
108. XY Liu XP Chu LM Mao 2006 Modulation of D2R-NR2B interactions in response to cocaine Neuron 52 897 909
109. K Mackie 2005 Cannabinoid receptor homo- and heterodimerization Life Sci 77 1667 1673
110. R Maggio M Scarselli F Novi MJ Millan GU Corsini 2003 Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole J Neurochem 87 631 641
111. R Maggio F Novi M Scarselli GU Corsini 2005 The impact of G-protein-coupled receptor hetero-oligomerization on function and pharmacology FEBS J 272 2939 2946
112. YP Maneuf AR Crossman JM Brotchie 1997 The cannabinoid receptor agonist WIN 55, 212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease Exp Neurol 148 265 270
113. D Marcellino P Carriba M Filip 2008 Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers: a combined neurochemical and behavioral analysis Neuropharmacology 54 815 823
114. GJ Marek 2004 Metabotropic glutamate 2/3 receptors as drug targets Curr Opin Pharmacol 4 18 22
115. FH Marshall 2001 Heterodimerization of G-protein-coupled receptors in the CNS Curr Opin Pharmacol 1 40 44
116. FH Marshall 2005 Is the GABA B heterodimer a good drug target? J Mol Neurosci 26 169 176
117. D Maurel L Comps-Agrar C Brock 2008 Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization Nat Methods 5 561 567
118. MJ Millan A Gobert A Newman-Tancredi F Lejeune D Cussac JM Rivet V Audinot T Dubuffet G Lavielle 2000 S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218, 231 and L741, 626 J Pharmacol Exp Ther 293 1048 1062 (Pubitemid 30417876)
119. G Milligan NJ Smith 2007 Allosteric modulation of heterodimeric G-protein-coupled receptors Trends Pharmacol Sci 28 615 620
120. S Miyamoto GE Duncan CE Marx JA Lieberman 2005 Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs Mol Psychiatry 10 79 104
121. GJ Mogenson DL Jones CY Yim 1980 From motivation to action: functional interface between the limbic system and the motor system Prog Neurobiol 14 69 97
122. S Mukhopadhyay HH McIntosh DB Houston AC Howlett 2000 The CB(1) cannabinoid receptor juxtamembrane C-terminal peptide confers activation to specific G proteins in brain Mol Pharmacol 57 162 170
123. CB Nemeroff 1980 Neurotensin: perchance an endogenous neuroleptic? Biol Psychiatry 15 283 302
124. EA Nimchinsky PR Hof WG Janssen JH Morrison C Schmauss 1997 Expression of dopamine D3 receptor dimers and tetramers in brain and in transfected cells J Biol Chem 272 29229 29237
125. A Nishi F Liu S Matsuyama M Hamada H Higashi AC Nairn P Greengard 2003 Metabotropic mGlu5 receptors regulate adenosine A2A receptor signaling Proc Natl Acad Sci USA 100 1322 1327
126. F Novi MJ Millan GU Corsini R Maggio 2007 Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D(2L) receptors are modified by co-transfection of D(3) receptors: potential role of heterodimer formation J Neurochem 102 1410 1424
127. B Pakkenberg 1990 Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics Arch Gen Psychiatry 47 1023 1028
128. JM Palacios 1983 Quantitative receptor autoradiography: application to the study of multiple serotonin receptors in rat cortex Adv Biochem Psychopharmacol 37 455 463
129. ST Patil L Zhang F Martenyi 2007 Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial Nat Med 13 1102 1107
130. VM Pickel J Chan CS Kearn K Mackie 2006 Targeting dopamine D2 and cannabinoid-1 (CB1) receptors in rat nucleus accumbens J Comp Neurol 495 299 313
131. D Piomelli 2003 The molecular logic of endocannabinoid signalling Nat Rev Neurosci 4 873 884
132. GJ Popken WE Bunney Jr SG Potkin EG Jones 2000 Subnucleus-specific loss of neurons in medial thalamus of schizophrenics Proc Natl Acad Sci USA 97 9276 9280
133. P Popoli A Pezzola M Torvinen R Reggio A Pintor L Scarchilli K Fuxe S Ferre 2001 The selective mGlu(5) receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopamine-lesioned rats and modulates the binding characteristics of dopamine D(2) receptors in the rat striatum: interactions with adenosine A(2a) receptors Neuropsychopharmacology 25 505 513
134. R Rimondini S Ferre SO Ogren K Fuxe 1997 Adenosine A2A agonists: a potential new type of atypical antipsychotic Neuropsychopharmacology 17 82 91
135. F Rodriguez de Fonseca I Del Arco JL Martin-Calderon MA Gorriti M Navarro 1998 Role of the endogenous cannabinoid system in the regulation of motor activity Neurobiol Dis 5 483 501
136. DL Rosin A Robeva RL Woodard PG Guyenet J Linden 1998 Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system J Comp Neurol 401 163 186
137. M Scarselli F Novi E Schallmach 2001 D2/D3 dopamine receptor heterodimers exhibit unique functional properties J Biol Chem 276 30308 30314
138. W Schultz 2002 Getting formal with dopamine and reward Neuron 36 241 263
139. JC Schwartz J Diaz C Pilon P Sokoloff 2000 Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions Brain Res Brain Res Rev 31 277 287
140. MA Schwarzschild L Agnati K Fuxe JF Chen M Morelli 2006 Targeting adenosine A(2A) receptors in Parkinson's disease Trends Neurosci 29 647 654
141. P Seeman J Schwarz JF Chen 2006 Psychosis pathways converge via D2high dopamine receptors Synapse 60 319 346
142. RP Sharma PG Janicak G Bissette CB Nemeroff 1997 CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder Am J Psychiatry 154 1019 1021
143. W Shen M Flajolet P Greengard DJ Surmeier 2008 Dichotomous dopaminergic control of striatal synaptic plasticity Science 321 848 851
144. T Shindou H Nonaka PJ Richardson A Mori H Kase M Ichimura 2002 Presynaptic adenosine A2A receptors enhance GABAergic synaptic transmission via a cyclic AMP dependent mechanism in the rat globus pallidus Br J Pharmacol 136 296 302
145. N Simola S Fenu PG Baraldi MA Tabrizi M Morelli 2006 Involvement of globus pallidus in the antiparkinsonian effects of adenosine A(2A) receptor antagonists Exp Neurol 202 255 257
146. P Sokoloff J Diaz B Le Foll O Guillin L Leriche E Bezard C Gross 2006 The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders CNS Neurol Disord Drug Targets 5 25 43
147. SM Stahl 2007 Beyond the dopamine hypothesis to the NMDA glutamate receptor hypofunction hypothesis of schizophrenia CNS Spectr 12 265 268
148. SM Stahl 2007 The genetics of schizophrenia converge upon the NMDA glutamate receptor CNS Spectr 12 583 588
149. SM Stahl 2008 Do dopamine partial agonists have partial efficacy as antipsychotics? CNS Spectr 13 279 282
150. V Sturm D Lenartz A Koulousakis H Treuer K Herholz JC Klein J Klosterkotter 2003 The nucleus accumbens: a target for deep brain stimulation in obsessive-compulsive- and anxiety-disorders J Chem Neuroanat 26 293 299 (Pubitemid 38077152)
151. DJ Surmeier WJ Song Z Yan 1996 Coordinated expression of dopamine receptors in neostriatal medium spiny neurons J Neurosci 16 6579 6591
152. DJ Surmeier J Ding M Day Z Wang W Shen 2007 D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons Trends Neurosci 30 228 235
153. TH Svensson 2000 Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs Brain Res Brain Res Rev 31 320 329
154. CA Tamminga A Carlsson 2002 Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis Curr Drug Targets CNS Neurol Disord 1 141 147
155. S Tanganelli G von Euler K Fuxe LF Agnati U Ungerstedt 1989 Neurotensin counteracts apomorphine-induced inhibition of dopamine release as studied by microdialysis in rat neostriatum Brain Res 502 319 324
156. S Tanganelli WT O'Connor L Ferraro C Bianchi L Beani U Ungerstedt K Fuxe 1994 Facilitation of GABA release by neurotensin is associated with a reduction of dopamine release in rat nucleus accumbens Neuroscience 60 649 657
157. M Torvinen D Marcellino M Canals LF Agnati C Lluis R Franco K Fuxe 2005 Adenosine A2A receptor and dopamine D3 receptor interactions: evidence of functional A2A/D3 heteromeric complexes Mol Pharmacol 67 400 407
158. M Uchigashima M Narushima M Fukaya I Katona M Kano M Watanabe 2007 Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum J Neurosci 27 3663 3676
159. K van Kuyck L Gabriels P Cosyns L Arckens V Sturm S Rasmussen B Nuttin 2007 Behavioural and physiological effects of electrical stimulation in the nucleus accumbens: a review Acta Neurochir Suppl 97 375 391
160. FX Vollenweider MF Vollenweider-Scherpenhuyzen A Babler H Vogel D Hell 1998 Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action Neuroreport 9 3897 3902
161. G von Euler 1991 Biochemical characterization of the intramembrane interaction between neurotensin and dopamine D2 receptors in the rat brain Brain Res 561 93 98
162. A Whitty 2008 Cooperativity and biological complexity Nat Chem Biol 4 435 439
163. DH Williams E Stephens DP O'Brien M Zhou 2004 Understanding noncovalent interactions: ligand binding energy and catalytic efficiency from ligand-induced reductions in motion within receptors and enzymes Angew Chem Int Ed Engl 43 6596 6616
164. JR Williamson 2008 Cooperativity in macromolecular assembly Nat Chem Biol 4 458 465
165. KA Young KF Manaye C Liang PB Hicks DC German 2000 Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia Biol Psychiatry 47 944 953
166. AW Zuardi JA Crippa JE Hallak FA Moreira FS Guimaraes 2006 Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug Braz J Med Biol Res 39 421 429
167. AW Zuardi JE Hallak SM Dursun SL Morais RF Sanches RE Musty JA Crippa 2006 Cannabidiol monotherapy for treatment-resistant schizophrenia J Psychopharmacol 20 683 686